The 3CTN EDI Framework and Toolkit is Launched
The Canadian Cancer Clinical Trials Network (3CTN) and its collaborative partners are thrilled to announce the launch of an Equity, Diversity, and Inclusion (EDI) Framework and companion Toolkit designed to support the Canadian research community in embedding EDI best practices within clinical trial conduct! This comprehensive EDI Framework and Toolkit resource are the products of an expert working group comprised of 3CTN members, trial sponsors, and people with lived experience from underrepresented communities. The resulting materials are available and accessible on the 3CTN website for the benefit of all in the research community. To access, please go to https://3ctn.ca/equity-diversity-and-inclusion-in-clinical-trials/.
Recognizing Outstanding Contributions to the Canadian Cancer Research Community
The CCRA Awards, initiated in 2011, recognize and celebrate, on a biennial basis, individuals who have had a remarkable impact on cancer research and the cancer research community. We are seeking nominees for our four award categories: outstanding research, distinguished se... Read More »
The CCRA Awards, initiated in 2011, recognize and celebrate, on a biennial basis, individuals who have had a remarkable impact on cancer research and the cancer research community. We are seeking nominees for our four award categories: outstanding research, distinguished se... Read More »
2018 Investment in Cancer Research: Report Released
Today, CCRA released its latest report on the investment in cancer research. It reveals that $491M was invested in cancer research in 2018. Although a slight increase since 2017 (up $17M), the investment has been fairly constant over the past five years.
This year's report includes some new analyses, which quantify the cancer-... Read More »
Today, CCRA released its latest report on the investment in cancer research. It reveals that $491M was invested in cancer research in 2018. Although a slight increase since 2017 (up $17M), the investment has been fairly constant over the past five years.
This year's report includes some new analyses, which quantify the cancer-... Read More »